KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Inventory (2020 - 2026)

Moderna (MRNA) has disclosed Inventory for 7 consecutive years, with $146.0 million as the latest value for Q1 2026.

  • For Q1 2026, Inventory rose 14.06% year-over-year to $146.0 million; the TTM value through Mar 2026 reached $146.0 million, up 14.06%, while the annual FY2025 figure was $153.0 million, 30.77% up from the prior year.
  • Inventory hit $146.0 million in Q1 2026 for Moderna, down from $153.0 million in the prior quarter.
  • Across five years, Inventory topped out at $2.1 billion in Q3 2022 and bottomed at $117.0 million in Q4 2024.
  • Average Inventory over 5 years is $661.6 million, with a median of $399.0 million recorded in 2024.
  • Year-over-year, Inventory soared 293.12% in 2022 and then plummeted 78.71% in 2023.
  • Moderna's Inventory stood at $949.0 million in 2022, then crashed by 78.71% to $202.0 million in 2023, then plummeted by 42.08% to $117.0 million in 2024, then surged by 30.77% to $153.0 million in 2025, then dropped by 4.58% to $146.0 million in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $146.0 million, $153.0 million, and $332.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.